570 Shares in Novo Nordisk A/S $NVO Acquired by Maseco LLP

Maseco LLP purchased a new position in shares of Novo Nordisk A/S (NYSE:NVO) in the 2nd quarter, Holdings Channel reports. The firm purchased 570 shares of the company’s stock, valued at approximately $39,000.

Several other institutional investors have also modified their holdings of NVO. Revolve Wealth Partners LLC raised its stake in Novo Nordisk A/S by 8.7% in the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock valued at $214,000 after buying an additional 200 shares in the last quarter. Park Square Financial Group LLC acquired a new stake in shares of Novo Nordisk A/S during the 4th quarter worth about $29,000. Aegis Wealth Management LLC purchased a new stake in Novo Nordisk A/S during the fourth quarter worth approximately $479,000. Lighthouse Financial LLC acquired a new position in Novo Nordisk A/S in the fourth quarter valued at approximately $1,811,000. Finally, NorthCrest Asset Manangement LLC increased its stake in Novo Nordisk A/S by 4.4% in the fourth quarter. NorthCrest Asset Manangement LLC now owns 11,663 shares of the company’s stock valued at $1,003,000 after purchasing an additional 495 shares during the last quarter. 11.54% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several analysts have recently weighed in on the stock. Wall Street Zen downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. HSBC downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $57.00 price objective for the company. in a research note on Thursday, July 31st. BNP Paribas upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday, August 13th. BNP Paribas Exane raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 target price for the company in a research report on Wednesday, August 13th. Finally, Dbs Bank raised Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research report on Friday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, eleven have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $81.00.

Novo Nordisk A/S Stock Performance

NYSE NVO opened at $58.78 on Thursday. The firm has a market cap of $262.47 billion, a P/E ratio of 16.15, a P/E/G ratio of 2.26 and a beta of 0.66. Novo Nordisk A/S has a 52-week low of $45.05 and a 52-week high of $127.61. The business’s 50-day moving average price is $56.39 and its 200 day moving average price is $64.84. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 earnings per share for the quarter, topping analysts’ consensus estimates of $0.93 by $0.04. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%.The company had revenue of $11.69 billion during the quarter, compared to analysts’ expectations of $77.51 billion. On average, equities research analysts expect that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Cuts Dividend

The company also recently disclosed a semi-annual dividend, which was paid on Tuesday, August 26th. Shareholders of record on Monday, August 18th were paid a $0.4119 dividend. This represents a yield of 240.0%. The ex-dividend date of this dividend was Monday, August 18th. Novo Nordisk A/S’s payout ratio is currently 22.53%.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.